Skip To Main Content

Actualización normativa

En un entorno en constante cambio como el sistema de salud, es fundamental mantenerse al día con las nuevas normativas que afectan tanto a profesionales como a pacientes. En este espacio encontrará las leyes, decretos, resoluciones y acuerdos relacionados con el sistema de salud dinámico y en evolución.

También encontrará resúmenes, análisis y todo lo relacionado con la más reciente normatividad, para comprender el posible impacto de los cambios hacia los diferentes actores del sistema.

Ordenar por
Phòng Ngừa Bệnh Do Vi Khuẩn Và Virus Lây Lan Qua Đường Hô Hấp Và Vai Trò Không Thể Thiếu Của Vắc-xin

Phòng Ngừa Bệnh Do Vi Khuẩn Và Virus Lây Lan Qua Đường Hô Hấp Và Vai Trò Không Thể Thiếu Của Vắc-xin

Rare diseases : Dried Blood Spot (DBS)

Rare diseases : Dried Blood Spot (DBS)

DBS is a form of biosampling in which blood samples collected from a finger-prick lancet are blotted and dried on filter paper.1

These samples are then sent to analytical laboratories to be analysed using a variety of methods such as enzyme assays and polymerase chain reaction (PCR).2,3

Long-Term Efficacy and Safety of Dupixent in Moderate-to-Severe Atopic Dermatitis: 5-Year Open-Label Extension Study Results<sup>1</sup>

Long-Term Efficacy and Safety of Dupixent in Moderate-to-Severe Atopic Dermatitis: 5-Year Open-Label Extension Study Results

Atopic dermatitis (AD) is a chronic inflammatory skin condition that can significantly impact patients' quality of life. Dupixent (dupilumab) has emerged as a treatment for moderate-to-severe AD. This article summarizes the findings of a 5-year open-label extension study (Beck et al, 2024), providing insights into the long-term efficacy and safety profile of Dupixent for dermatologists managing patients with persistent AD.

Long-Term Efficacy and Safety of Dupixent in Moderate-to-Severe Atopic Dermatitis: 5-Year Open-Label Extension Study Results<sup>1</sup>

Long-Term Efficacy and Safety of Dupixent in Moderate-to-Severe Atopic Dermatitis: 5-Year Open-Label Extension Study Results

Atopic dermatitis (AD) is a chronic inflammatory skin condition that can significantly impact patients' quality of life. Dupixent (dupilumab) has emerged as a treatment for moderate-to-severe AD. This article summarizes the findings of a 5-year open-label extension study (Beck et al, 2024), providing insights into the long-term efficacy and safety profile of Dupixent for dermatologists managing patients with persistent AD.

Long-Term Efficacy and Safety of Dupixent in Moderate-to-Severe Atopic Dermatitis: 5-Year Open-Label Extension Study Results<sup>1</sup>

Long-Term Efficacy and Safety of Dupixent in Moderate-to-Severe Atopic Dermatitis: 5-Year Open-Label Extension Study Results

Atopic dermatitis (AD) is a chronic inflammatory skin condition that can significantly impact patients' quality of life. Dupixent (dupilumab) has emerged as a treatment for moderate-to-severe AD. This article summarizes the findings of a 5-year open-label extension study (Beck et al, 2024), providing insights into the long-term efficacy and safety profile of Dupixent for dermatologists managing patients with persistent AD.

DERM 360° Roundtable: Patient Reported Outcome Measures (PROMs) in Clinical Practice

DERM 360° Roundtable: Patient Reported Outcome Measures (PROMs) in Clinical Practice

3rd of December 2024

DERM 360° Roundtable: Patient Reported Outcome Measures (PROMs) in Clinical Practice

DERM 360° Roundtable: Patient Reported Outcome Measures (PROMs) in Clinical Practice

3rd of December 2024

Long-Term Efficacy and Safety of Dupixent in Moderate-to-Severe Atopic Dermatitis: 5-Year Open-Label Extension Study Results<sup>1</sup>

LIBERTY studieprogram på atopisk eksem

Atopic dermatitis (AD) is a chronic inflammatory skin condition that can significantly impact patients' quality of life. Dupixent (dupilumab) has emerged as a treatment for moderate-to-severe AD. This article summarizes the findings of a 5-year open-label extension study (Beck et al, 2024), providing insights into the long-term efficacy and safety profile of Dupixent for dermatologists managing patients with persistent AD.

Global Developments in Early Detection<br />of Autoimmune Type 1 Diabetes

Global Developments in Early Detection of Autoimmune Type 1 Diabetes

Curious about the characteristics of pre-symptomatic- and stage 3 Type 1 Diabetes? Interested in learning about the potential benefits of screening for autoimmune Type 1 Diabetes?

This short film gives you an overview of recent developments in diagnosis of Type 1 Diabetes, showcasing how early detection efforts can benefit those who need it the most.

Global Developments in Early Detection<br />of Autoimmune Type 1 Diabetes

Global Developments in Early Detection of Autoimmune Type 1 Diabetes

Curious about the characteristics of pre-symptomatic- and stage 3 Type 1 Diabetes? Interested in learning about the potential benefits of screening for autoimmune Type 1 Diabetes?

This short film gives you an overview of recent developments in diagnosis of Type 1 Diabetes, showcasing how early detection efforts can benefit those who need it the most.

Global Developments in Early Detection<br />of Autoimmune Type 1 Diabetes

Global Developments in Early Detection of Autoimmune Type 1 Diabetes

Curious about the characteristics of pre-symptomatic- and stage 3 Type 1 Diabetes? Interested in learning about the potential benefits of screening for autoimmune Type 1 Diabetes?

This short film gives you an overview of recent developments in diagnosis of Type 1 Diabetes, showcasing how early detection efforts can benefit those who need it the most.

Global Developments in Early Detection<br />of Autoimmune Type 1 Diabetes

Global Developments in Early Detection of Autoimmune Type 1 Diabetes

Curious about the characteristics of pre-symptomatic- and stage 3 Type 1 Diabetes? Interested in learning about the potential benefits of screening for autoimmune Type 1 Diabetes?

This short film gives you an overview of recent developments in diagnosis of Type 1 Diabetes, showcasing how early detection efforts can benefit those who need it the most.

Material diseñado por o para Sanofi Aventis de Colombia S.A., con fines educativos y dirigido a profesionales de la salud y personal administrativo del sector salud. Es estrictamente prohibido compartir este material con terceros.

Mayor información a disposición en el Departamento Médico:

En Colombia:

Sanofi-Aventis de Colombia S.A. Transversal 23 N° 97-73 - Edificio City Business. Piso 8. Bogotá D.C. Teléfono: 621 4400 - Fax: 744 4237

infomedica.colombia@sanofi.com

En Bolivia, Centro América y Caribe:

Sanofi-Aventis de Panamá S.A. Torre Evolution, piso 26, Calle 50 y Av. Aquilino de la Guardia Obarrio- Cuidad de Panamá, República de Panamá Telf.: (507) 382-9500. infomed.pac@sanofi.com

Sitio web: http://www.sanofi.com.pa/l/pa/sp/index.jsp

 

MAT-CO-2400825 V1.0 03/2024